Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome

Journal of Urology

Volumn 149, Issue 3, 1993, Pages 607-609

  Kelly, W K ^a   Scher, H I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

androgen antagonists; antigens; flutamide; prostate

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE LESION; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HIP FRACTURE; HORMONAL THERAPY; HUMAN; LYMPHADENOPATHY; MALE; MUSCLE WEAKNESS; NAUSEA; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

EID: 0027477695     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(17)36163-3     Document Type: Article

References (22)

1. J.I. Miller F.R. Ahmann G.W. Drach S.S. Emerson M.R. Bottaccini Clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer J. Urol. 147 1992 956
2. Kelly, W. K., Scher, H. I., Mazumdar, M. and Vlamis, V.: Prostate specific antigen (PSA) as a measure of disease outcome in hormone refractory stage D2 prostate cancer. J. Clin. Oncol., in press.
3. R.V. La Rocca R. Danesi M.R. Cooper C.A. Jamis-Dow M.W. Ewing W.M. Linehan C.E. Myers Effect of suramin on human prostate cancer cells in vitro J. Urol. 145 1991 393
4. H.I. Scher T. Curley N. Geller C. Engstrom D.D. Dershaw S.-Y. Lin K. Fitzpatrick J. Nisselbaum M. Schwartz L. Bezirdjian M. Eisenberger Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease J. Clin. Oncol. 8 1990 1830
5. D. Mannini P. Maver E. Aiello G. Corrado F. Vecchi B. Bellanova M. Marengo Spontaneous circadian fluctuations of prostatic specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer Urol. Res. 16 1988 9
6. J.E. Oesterling Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate J. Urol. 145 1991 907
7. G.W. Chodak Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma Urology 33 suppl. 5 1989 42
8. A. Manni R.J. Santen A. Boucher A. Lipton H. Harvey M. Simmonds D. White R. Gordon T. Ronher J. Drago J. Wettlaufer L.M. Glode Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial Anticancer Res. 5 1985 161
9. C.D. Taylor D.L. Trump D.L. Citrin P. Elson E. Messing K. Cummings V.C. Jordan Survival (S) impact of continued testicular androgen suppression in refractory prostate cancer Proc. Amer. Soc. Clin. Oncol. 8 1989 129
10. M.E. Leo D.L. Bilhartz E.J. Bergstralh J.E. Oesterling Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J. Urol. 145 1991 802
11. C.Y. Young B.T. Montgomery P.E. Andrews S.D. Qui D.L. Bilhartz D.J. Tindall Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP Cancer Res. 51 1991 3748
12. A.L. Schuurmans J. Bolt J. Veldscholte E. Mulder Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion J. Steroid Biochem. Mol. Biol. 37 1990 849
13. N. Olea K. Sakabe A.M. Soto C. Sonnenschein The proliferative effect of “anti-androgens” on the androgen-sensitive human prostate tumor cell line LNCaP Endocrinology 126 1990 1457
14. M.E. Gleave J.T. Hsieh H.C. Wu A.C. von Eschenbach L.W.K. Chung Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors Cancer Res. 52 1992 1598
15. J. Vendscholte C.A. Berrevoets A.O. Brinkmann J.A. Grootegoed E. Mulder Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation Biochemistry 31 1992 2393
16. W.W. He L.M. Fischer S. Sun D.L. Bilhartz X.P. Zhu C.Y.F. Young D.B. Kelley D. Tindall J.: Molecular cloning of androgen receptors from divergent species with a polymerase chain reaction technique: complete cDNA sequence of the mouse androgen receptor and isolation of androgen receptor cDNA probes from dog, guinea pig and clawed frog Biochem. Biophys. Res. Comm. 171 1990 697
17. J.R. Newmark D.O. Hardy D.C. Tonb B.S. Carter J.I. Epstein W.B. Isaacs T.R. Brown E.R. Barrack Androgen receptor gene mutations in human prostate cancer Proc. Natl. Acad. Sci. 89 1992 6319
18. J. Veldscholte C. Ris-Stalpers G.G.J.M. Kuiper G. Jenster C. Berrevoets E. Claassen H.C.J. van Rooij J. Trapman A.O. Brinkmann E. Mulder A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens Biochem. Biophys. Res. Comm. 173 1990 534
19. I.C. Henderson J.R. Harris D.W. Kinne S. Heilman Cancer of the breast chapt. 38 V.T. DeVita Jr. S. Heilman S.A. Rosenberg Cancer: Principles and Practice of Oncology 3rd ed. 1989 J. B. Lippincott Co. Philadelphia 1197 1268
20. V.C. Jordan M.-H. Jeng S.-Y. Jiang J. Yingling A.L. Stella Hormonal strategies for breast cancer: a new focus on the estrogen receptor as a therapeutic target Sem. Oncol. 19 1992 299
21. M.M. Gottardis V.C. Jordan Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration Cancer Res. 48 1988 5183
22. E.D. Crawford M.A. Eisenberger D.G. McLeod J.T. Spaulding R. Benson F.A. Dorr B.A. Blumenstein M.A. Davis P.J. Goodman A controlled trial of leuprolide with and without flutamide in prostatic carcinoma New Engl. J. Med. 321 1989 419